GeneFerm Biotechnology (Taiwan) Performance
| 1796 Stock | TWD 54.80 0.20 0.36% |
On a scale of 0 to 100, GeneFerm Biotechnology holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of 0.13, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GeneFerm Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding GeneFerm Biotechnology is expected to be smaller as well. Please check GeneFerm Biotechnology's semi deviation, coefficient of variation, jensen alpha, as well as the relationship between the downside deviation and standard deviation , to make a quick decision on whether GeneFerm Biotechnology's current trending patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in GeneFerm Biotechnology Co are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, GeneFerm Biotechnology showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 348 M | |
| Total Cashflows From Investing Activities | -145.3 M |
GeneFerm |
GeneFerm Biotechnology Relative Risk vs. Return Landscape
If you would invest 4,560 in GeneFerm Biotechnology Co on December 26, 2024 and sell it today you would earn a total of 940.00 from holding GeneFerm Biotechnology Co or generate 20.61% return on investment over 90 days. GeneFerm Biotechnology Co is generating 0.3803% of daily returns and assumes 2.8577% volatility on return distribution over the 90 days horizon. Simply put, 25% of stocks are less volatile than GeneFerm, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GeneFerm Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeneFerm Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GeneFerm Biotechnology Co, and traders can use it to determine the average amount a GeneFerm Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 1796 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.86 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average GeneFerm Biotechnology is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GeneFerm Biotechnology by adding it to a well-diversified portfolio.
GeneFerm Biotechnology Fundamentals Growth
GeneFerm Stock prices reflect investors' perceptions of the future prospects and financial health of GeneFerm Biotechnology, and GeneFerm Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneFerm Stock performance.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0534 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 41.46 M | |||
| Price To Earning | 53.28 X | |||
| Price To Book | 2.94 X | |||
| Price To Sales | 4.16 X | |||
| Revenue | 522.33 M | |||
| EBITDA | 123.07 M | |||
| Cash And Equivalents | 619.1 M | |||
| Cash Per Share | 15.32 X | |||
| Total Debt | 31.25 M | |||
| Debt To Equity | 0.72 % | |||
| Book Value Per Share | 19.62 X | |||
| Cash Flow From Operations | 112.23 M | |||
| Earnings Per Share | 2.18 X | |||
| Total Asset | 1.32 B | |||
About GeneFerm Biotechnology Performance
Evaluating GeneFerm Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if GeneFerm Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GeneFerm Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. The company was founded in 1999 and is based in Taipei City, Taiwan. GENEFERM BIOTECHNOLOGY operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about GeneFerm Biotechnology performance evaluation
Checking the ongoing alerts about GeneFerm Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GeneFerm Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 57.0% of the company shares are owned by insiders or employees |
- Analyzing GeneFerm Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneFerm Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining GeneFerm Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeneFerm Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneFerm Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeneFerm Biotechnology's stock. These opinions can provide insight into GeneFerm Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GeneFerm Stock Analysis
When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.